chrisvoncsefalvay/vaers-outcomes huggingface dataset:
"feeling that I have been out all night binge drinking".  States he has a feeling of being disoriented, exhaustion and "slow".  States he feels he is not thinking clearly and his appetite has decreased.  States he had the COVID vaccine 4 days ago and the symptoms started 3 days ago.  States he has slept for 15 hours 3 days ago and has been sleeping a lot since then.  Denies fever, chills, headaches, joint or muscle pain, abdominal pain, N/V/D.  States he has been pushing fluids at home.
Patient states he "broke out" with itchy, red hives about an hour after receiving flu vaccine. Patient came back to pharmacy 2 days later and did present with rash. Suggested he try oral BENADRYL and contact PCP.
Case number PHEH2013US011413, is an initial spontaneous report received from a pharmacist on 21 May 2013. This case refers to a patient of unspecified age and gender. The pharmacist stated that they found an unused vial of Men A lyophilized powder component of MENVEO, (batch number: not reported). The pharmacist was unsure if the patient was administered only the liquid component of MENVEO. No adverse event was reported. No other information available.
Blisters in mouth; Blisters all over lips; chills; Fever to 102F; Injection arm sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Injection arm sore), CHILLS (chills), PYREXIA (Fever to 102F), ORAL MUCOSAL BLISTERING (Blisters in mouth) and BLISTER (Blisters all over lips) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045A21A) for COVID-19 vaccination.     The patient's past medical history included Blood pressure high. Concurrent medical conditions included Drug allergy (Erythromycin, Amoxicillin, Darvocet).    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced VACCINATION SITE PAIN (Injection arm sore). On 21-Mar-2021, the patient experienced CHILLS (chills) and PYREXIA (Fever to 102F). On 23-Mar-2021, the patient experienced ORAL MUCOSAL BLISTERING (Blisters in mouth) and BLISTER (Blisters all over lips). On 22-Mar-2021, PYREXIA (Fever to 102F) was resolving. At the time of the report, VACCINATION SITE PAIN (Injection arm sore), CHILLS (chills), ORAL MUCOSAL BLISTERING (Blisters in mouth) and BLISTER (Blisters all over lips) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Mar-2021, Body temperature increased: 102f High. On 22-Mar-2021, Body temperature increased: 101f High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications  provided by the reporter included high blood pressure medications. Treatment for the event Blisters in mouth and all over lips included Abreva.
Information has been received from a RN concerning a 4 year old pt described as healthy who on 02/01/05 was vaccinated with a dose of varicella virus vaccine live. Within 24 hours of vaccination on approximately 02/02/05 the pt developed a rash with pimple like bumps filled with fluid lightly scattered over the body which caused itching. Unspecified medical attention was sought, Rx Tx included baths and oral Benadryl. AT the time of the report, the pt had not yet recovered. There was no product quality complaint involved. Additional information has been requested.
Information has been received from a woman in a doctor's office and a physician concerning an 18 month 18 month old caucasian male patient with no past medical history and no known allergies who on 20 SEP 2001 was vaccinated IM in the left thigh with the first dose (lot number 635892/1197K) of pneumococcal vaccine 23 polyvalent. Concomitant therapy on 20 SEP 2001 included the fourth dose (lot number 57043 reported, invalid for the product) in the left thigh of hib conjugate vaccine and the fourth dose (lot number A992A2) IM in the right thigh of diphtheria toxoid/pertussis vaccine/tetanus toxoid. There were no illnesses at the time of vaccination. On 21 SEP 2001, the patient developed a swollen right thigh (also reported as a swollen left thigh), which was characterized by erythema, warmth and pain. Subsequently, on 22 SEP 2002, the patient related to the therapy with pneumococcal vaccine 23 polyvalent, but was a reaction to the diphtheria toxoid/pertussis vaccine/tetanus toxoid. No further information is available.
This spontaneous report was received from a nurse refers to a female patient of unknown age. No concurrent condition or medical history was reported. On 15-APR-3013, the patient was vaccinated with GARDASIL (dose 1, dose and route of administration not provided). On 29-MAY-2013, the patient was vaccinated with GARDASIL (dose 2, dose and route of administration not provided). No concomitant therapy was reported. The patient had did not experience any adverse effects. The patient was going to receive a third dose of GARDASIL on 29-JUL-2015. The outcome of the event was unknown. No product quality issue was involved. Additional information has been requested.
-Extreme fatigue  -Fever over 100 degrees -Body aches  -Chills
Soreness in arm,  general chills especially in feet. Most of it a day after vaccine taken.
Patient admitted to hospital on 11/19/2021 Presented with confusion and  Decreased responsiveness. Patient was treated with TYLENOL, Benzonatate.
Patient states that Right arm became swollen and painful, then began to hurt deep inside the muscle from the injection site to the wrist, patient still has pain in her right arm when she lifts the arm above her shoulder.  Patient also states that a bruise developed one month after receiving the shot.  On physical exam today, injection site is WNL.  Not painful to touch.  Recommend patient follow up with primary care physician at next appointment.  Patient has appointment 07/14/2009.
Pt reports itching and hives. Pt taking BENADRYL. Pt currently recovering without professional medical care.
No additional adverse events.; Caller is office manager who reported temperature excursion for GARDASIL 9. One dose of vaccine had been administered. Product "not supported" per evaluation in TE case 02165317. No other details available. No additional adverse events. No product qu; This spontaneous report was received from an office manger and refers to a 16-year-old male patient. The patient's concurrent conditions, medical history and concomitant therapies were not reported. There was no information regarding the patient's allergies or drug reactions.  On 12-MAY-2022, the patient was vaccinated with one dose of improperly stored hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot #U008900, expiration date: 12-AUG-2023, (strength, exact dose, dose #, route and site of administration were not provided) for prophylaxis (product storage error). The temperature and the time frame for the excursion was not provided. It was unknown if there was a previous excursion. No additional adverse events was provided (no adverse event). On 20-MAY-2022 inbound call was received from the office manager. She stated that additional information would be available via Vaccine Adverse Event Reporting System (VAERS). Additional information has been requested.
Neurological sequela; A spontaneous report was received from a healthcare professional concerning a  female patient of unspecified age  who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events neurological sequela, started on the left side of the face and spread all over the body/neurological disorder.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 21 Jan 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: unknown) via unknown route for prophylaxis of COVID-19 infection.  On 29 Jan 2021, the patient experienced the event(s) neurological sequela, started on the left side of the face and spread all over the body.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), neurological sequela, started on the left side of the face and spread all over the body was unknown.
On the first dosage, I had experienced slight pain and bruising around the injection site. This was easily fixed by icing the area.   The second dose had severe side effects such as a swollen, red, painful area around the injection site that was hot to the touch. A little bit of edema was noticeable as well with itchiness. Followed a fever that persisted for a day and a half, body aches, and a dull headache.
Has diabetes, received a FLUZONE for 8 yro-no problems-PM 10/5-50 cent swelling, hot tired, achy, went on to school, felt better by Thurs. 10/8, swelling better also by 10/8.
2weeks after receiving the COVID vaccine I broke out with shingles on my right lower abdomen and back
the patient was administered improperly stored PROQUAD; This spontaneous report was received from a nurse referring to a 5 years old female patient. No information was provided regarding the patient's pertinent medical history, concomitant medications and drug reactions or allergies.  On 03-SEP-2020, the patient was vaccinated with improperly stored dose of measles, mumps, rubella and varicella virus vaccine live (rHA) (PROQUAD) (strength, dose and route were not reported; lot # T012422, expiration date 06-OCT-2021) for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent (lot number and expiration date were not reported).  The administered dose of the vaccine experienced a temperature excursion of 6 degrees Fahrenheit to 14 degrees Fahrenheit (12.15 degrees Fahrenheit) for 50 minutes, as recorded by a data logger. There was no previous temperature excursion reported.
After first covid vaccine I developed shingles between the first and second doses in the right thigh .  I also experienced (and still am experiencing) mobility problems with the right leg.  Coincidentally? this is the leg that has had a total hip replacement 3 years ago. Shingles rash has not completely gone away.
I received my second dose of the Pfizer vaccine at 3:00 p.m. on 10/1/21. By  around 7:00 p.m. my left arm (injection site) was extremely sore and a headache. As the night went on I had fever, chills, cold sweats, headache and swollen lymph nodes in neck and under arms. 10/2/21-still all symptoms present as on 10/1/21 and add no taste and barely able to smell. These symptoms lasted until 10/3/21 afternoon around 4:00 p.m. I still cannot fully taste or smell and my lymph nodes are still somewhat swollen or sore.
Pt recv vax on 2/11/99; on 2/13/99 pt exp sore throat, joint/muscle pains, flu-like sx; on 2/23/99 pt exp tendinitis, swelling of wrist/ thumb/ elbow joints, sore fingers; tx=Ibuprofen
4 months post vax, pt developed varicella, diagnosed on 06/05/2000.
Itchy pain under left breast. Rash under left breast that grew larger over the next few days. Increased pain under left breast and also on left back.
A week after the vaccination, I started to have pressure in my left eye.  They at first thought it was a sinus infection.  However, by Thursday, September 3rd, I have shadowed vision.  Could not see clearly. Went to Medical Center, Eye Dr, and then a Specialist. After many tests including EKG, MRI, MRA, Blood Work, etc.  It was determined I had an enflamed optic nerve.  All other causes were ruled out. Date of vaccination and onset of symptoms determined vaccination was the cause.  Still have not regained full vision in left eye.
Experienced sudden simple onset focal seizure as soon as vaccine was injected into muscle. This was not because of the needle prick but happened afterwards.
This spontaneous report as received from a licensed practical nurse refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history and concurrent conditions was provided. On unknown dates, the patients received unspecified doses of RECOMBIVAX HB immunization series, lot number L009155, expiration date: 29-OCT-2016, lot number L045117, expiration date: 16-OCT-2018, lot number M001578, expiration date: 20-NOV-2018, lot number reported as M001579, expiration date: 05-OCT-2018 and lot number L019299, expiration date: 15-APR-2017, (dose, route of administration and injection site were not provided. There were no concomitant medications reported. It was stated that the vaccine underwent temperature excursion of 49.1 degrees Fahrenheit for 1 hour 7 minutes. The excursion was captured using digital data logger. No previous temperature excursion was reported. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Adult received pediatric dose of Pfizer COVID-19 vaccine as a booster dose. Patient will come back in 21 days to received full adult dose.
she already had a scratchy throat and it was discovered it was caused by RSV; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A female patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown, single (Batch/Lot number: unknown) for immunisation; for immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: THROAT IRRITATION (non-serious), outcome "unknown", described as "she already had a scratchy throat and it was discovered it was caused by RSV".  Clinical course: Patient wanted to know about the different COVID-19 boosters that are available. Patient said she had the RSV vaccine right now and she went to get the COVID-19 but she couldn't get it because she already had a scratchy throat and it was discovered it was caused by RSV. Patient would like to know how long she has to wait to try to get the vaccine afterwards.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
"Covid arm"  Red, swollen lump, about 3 inch diameter, itchy, sore, hard, hot to touch, about 1 week after injection. Underarm soreness, general discomfort in upper arm that was not present before 7 days after the shot
4/19/20/21- vertigo, nausea, vomiting, headache, head fog, abdominal pain, fatigue, chills, low grade fever - Meclizine and Advil 4/22/2021- headache and head fog - Meclizine and Advil
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 60-decade-old male patient who received SHINGRIX for prophylaxis. On 6th March 2019, the patient received the 2nd dose of SHINGRIX. In March 2019, less than a week after receiving SHINGRIX, the patient experienced injection site pain, injection site warmth, injection site erythema, weakness, muscle pain and general body pain. On an unknown date, the outcome of the injection site pain, injection site warmth, injection site erythema, weakness, muscle pain and general body pain were unknown. It was unknown if the reporter considered the injection site pain, injection site warmth, injection site erythema, weakness, muscle pain and general body pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient was in late 60s received 2nd dose of SHINGRIX yesterday and experienced the redness, hot and pain at the injection side and experiencing tiredness, muscle pain, body ache. All that the patient need something that would wade her pain. The patient asked if they could receive pain killer ADVIL or TYLENOL and how long would this condition last. This case has been linked to the case US2019AMR042890, reported by same reporter (wife's case).
pt recv vax & w/in 24hr of vax pt devel a rash;
Severe fever and muscle ache for 24 hours.   I have not experienced this in over 10 years!   If I had known, I would NEVER had received, what I consider to be a foreign invasion of poison  into  my body.  I regret taking the vaccine!!
First dose 4 month ago and missed second dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (First dose 4 month ago and missed second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (First dose 4 month ago and missed second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (First dose 4 month ago and missed second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant products were reported.  No treatment information was provided.
Patient reports extreme night sweats starting approximately 4 days post vaccination.  Incidence has been >5 nights/ week.  Denies any associated chest pain/ palpitations, dyspnea, rash, dysuria, hematuria, or abdominal pain.
One day after receiving the injection, a bump appeared at the injection site,lasting about a day. It disappeared and then retrurned about 1 week later.  The arm was itchy and a raised rash appeared, lasting over a month.  Application of OTC hydrocortisone cream relieved the redness and itching.
Knot has developed on arm where the vaccine was administered -   the arm has become swollen and the pain is increasing and not decreasing pain.
sore arm; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID.  A female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Past drug history included: Miralax, reaction(s): "reaction". Vaccination history included: Bnt162b2 (dose 1), for COVID-19 immunization, reaction(s): "Pain in arm". The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "sore arm".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300080183 Same patient/event, different vaccine dose;US-PFIZER INC-PV202300080185 Same patient/event, different vaccine dose;
No adverse event; lower than authorized dose of Moderna bivalent vaccine administered to patients; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (lower than authorized dose of Moderna bivalent vaccine administered to patients) and NO ADVERSE EVENT (No adverse event) in an elderly patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 061F22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 27-Oct-2022, the patient experienced ACCIDENTAL UNDERDOSE (lower than authorized dose of Moderna bivalent vaccine administered to patients). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (lower than authorized dose of Moderna bivalent vaccine administered to patients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (lower than authorized dose of Moderna bivalent vaccine administered to patients).    Concomitant product use was not provided by the reporter.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-666277, US-MODERNATX, INC.-MOD-2022-666284, US-MODERNATX, INC.-MOD-2022-666280, US-MODERNATX, INC.-MOD-2022-666063, US-MODERNATX, INC.-MOD-2022-666248, US-MODERNATX, INC.-MOD-2022-666249, US-MODERNATX, INC.-MOD-2022-666250, US-MODERNATX, INC.-MOD-2022-666251, US-MODERNATX, INC.-MOD-2022-666252, US-MODERNATX, INC.-MOD-2022-666255, US-MODERNATX, INC.-MOD-2022-666279, US-MODERNATX, INC.-MOD-2022-666295, US-MODERNATX, INC.-MOD-2022-666286, US-MODERNATX, INC.-MOD-2022-666283, US-MODERNATX, INC.-MOD-2022-666282, US-MODERNATX, INC.-MOD-2022-666281 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-666277:Patient 7 US-MODERNATX, INC.-MOD-2022-666280:Patient 16 US-MODERNATX, INC.-MOD-2022-666284:patient 9 US-MODERNATX, INC.-MOD-2022-666063:Patient 1 US-MODERNATX, INC.-MOD-2022-666248:Patient 2 US-MODERNATX, INC.-MOD-2022-666249:Patient 3 US-MODERNATX, INC.-MOD-2022-666250:Patient 4 US-MODERNATX, INC.-MOD-2022-666251:Patient 5 US-MODERNATX, INC.-MOD-2022-666252:Patient 6 US-MODERNATX, INC.-MOD-2022-666255:Patinet 7 US-MODERNATX, INC.-MOD-2022-666279:Patient 15 US-MODERNATX, INC.-MOD-2022-666295:Patient 12 US-MODERNATX, INC.-MOD-2022-666286:Patient 10 US-MODERNATX, INC.-MOD-2022-666283:Patient 8 US-MODERNATX, INC.-MOD-2022-666282:Patient 18 US-MODERNATX, INC.-MOD-2022-666281:patient 17
Acute right index finger digital ischemia after initial complete numbness from PIP joint distally absent any previous symptoms ever.   Recurrence Jan 20 of same symptoms.  Suspect antibody complex clot blocking terminal branches of digital arteries.
9 days post vax fever-lt shoulder pain-APAP -saw MD;blood work;pt started on ATB;given med for shoulder;pain rt shoulder, sore throat, congestion;also hot lt great toe;MD did x-rays showed soft tissue swelling-joint pain;+RA,n,effusion knee
1/21/21 6pm sore and aching arm, hurts when touched and when I raised my arm
On day 11 after taking a shower, I noticed a red patch in the shape of a 2" circle near the injection site. It did not itch or have pain, but it was just there.  Day 13 and it has definitely faded and can hardly be seen.
This spontaneous report as received from a registered nurse refers to a 14 year old patient (unspecified gender). On 15-JUN-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (dose and route were not provided) (lot # K008931 exp. 04-MAR-2017; lot # K009482 exp. 06-MAR-2017) which was exposed to below 36F for 361.81 hours. The nurse was requesting assistance in determining revaccination. In addition, excursion below 32F (31.2F) started on 13-JUL-2015. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.